Bacteria-cancer interactions: bacteria-based cancer therapy

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Cancer therapeutics face challenges including toxicity, deep tissue penetration, and drug resistance.
• Targeted therapy and immunotherapy show promise but have limitations.
• Live tumor-targeting bacteria present a unique alternative to overcome these therapeutic hurdles.

Purpose of the Study:

• To review the benefits and challenges of using live tumor-targeting bacteria as an anticancer approach.
• To discuss the mechanisms by which bacteria interact with the tumor microenvironment to induce regression.
• To explore methods for engineering bacteria to enhance efficacy and safety.

Main Methods:

• Review of existing literature on tumor-targeting bacteria in cancer therapy.
• Analysis of bacterial-tumor microenvironment interactions.
• Discussion of genetic engineering and synthetic biology approaches for bacterial modification.
• Summary of preclinical and clinical trial data.

Main Results:

• Bacteria preferentially accumulate and proliferate in tumors, initiating antitumor immune responses.
• Engineered bacteria can be programmed to produce and deliver specific anticancer agents.
• Combination therapy with bacteria shows potential for improved clinical outcomes.
• Various engineering strategies exist to boost bacterial efficacy and safety.

Conclusions:

• Live tumor-targeting bacteria represent a versatile and promising therapeutic strategy for various cancer types.
• Further research and clinical trials are essential to fully realize the potential of this approach.
• Bacterial-based cancer therapies offer a novel avenue for overcoming current treatment limitations.